Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Insulin-Like Growth Factors and Their Binding Proteins in Tumors and Ascites of Ovarian Cancer Patients: Association With Response To Neoadjuvant Chemotherapy

  • Yunusova, Natalia V (Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences) ;
  • Villert, Alisa B (Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences) ;
  • Spirina, Liudmila V (Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences) ;
  • Frolova, Alena E (Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences) ;
  • Kolomiets, Larisa A (Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences) ;
  • Kondakova, Irina V (Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences)
  • Published : 2016.12.01
⟨ Previous Next ⟩

Abstract

Purpose: Tumor cell growth and sensitivity to chemotherapy depend on many factors, among which insulin-like growth factors (IGFs) may play important roles. The aim of the present study was to evaluate the levels of insulin-like growth factors (IGFs) and IGF binding proteins (IGFBPs) in primary tumors and ascites as predictors of response to neoadjuvant chemotherapy in ovarian cancer (OC) patients. Materials and Methods: Tumor tissue samples and ascitic fluid were obtained from 59 patients with advanced OC. The levels of IGF-I, IGF-II, IGFBP-3, IGFBP-4 and PAPP-A were determined using ELISA kits. Taking into account the data on expression of these IGF-related proteins and outcome, logistic regression was performed to identify predictors of response to neoajuvant chemotherapy. Results: Human ovarian tumors expressed IGFs, IGFBP-3, IGFBP-4 and PAPP-A and these proteins were also present in ascites fluid and associated with its volume. IGFs and IGFBPs in ascites and soluble PAPP-A might play a key role in ovarian cancer progression. However, levels of proteins of the IGF system in tumors were not significant predictors of objective clinical response (oCR). Univariate analysis showed that the level of IGF-I in ascites was the only independent predictor for oCR. Conclusion: The level of IGF-I in ascites was shown to be an independent predictor of objective clinical response to chemotherapy for OC patients treated with neoadjuvant chemotherapy and debulking surgery.

Keywords

References

  1. Angioli R, Plotti F, Capriglione S, et al (2013). Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma?. Gynecol Oncol, 128, 579-83. https://doi.org/10.1016/j.ygyno.2012.11.040
  2. Avril N, Sassen S, Schmalfeldt B, et al (2005). Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol, 23, 7445-53. https://doi.org/10.1200/JCO.2005.06.965
  3. Bold HB, Conover CA (2011). Overexpression of pregnancyassociated plasma protein-A in ovarian cancer. Endocrinology, 152, 1470-8. https://doi.org/10.1210/en.2010-1095
  4. Chen JW, Ledet T, Orskov H, et al (2003). A high sensitive and specific assay for determination of IGF-I bioactivity in human serum. Am J Physiol Endocrinol Metab, 284, 1149-55. https://doi.org/10.1152/ajpendo.00410.2002
  5. Eckstein N, Servan K, Hildebrandt B, et al (2009). Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. Cancer Res, 69, 29996-3003.
  6. Feigenberg T, Clarke B, Virtanen C, et al (2014). Molecular profiling and clinical outcome of high-grade serous ovarian cancer presenting with low- versus high-volume ascites. Biomed Res Int, 367103.doi: 10/1155/2014/367103.
  7. Feng Z, Wen H, Bi R, et al (2016). Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients, BMC Cancer, 16, 43. https://doi.org/10.1186/s12885-016-2070-2
  8. Firth SM, Baxter RC (2002). Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev, 23, 824-54. https://doi.org/10.1210/er.2001-0033
  9. Gasowska-Bodnar A, Bodnar L, Dabek A, et al (2014). Survivin expression as a prognostic factor in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy. Int J Gynecol Cancer, 24, 687-96. https://doi.org/10.1097/IGC.0000000000000108
  10. Huang GS, Brouwer-Visser J, Ramirez MJ, et al (2010). Insulinlike growth factor 2 expression modulates taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer. Clin Cancer Res, 16, 2999-3010. https://doi.org/10.1158/1078-0432.CCR-09-3233
  11. Morimoto A, Nagao S, Kogiku A, et al (2016). A preoperative low cancer antigen 125 level (<25.8 mg/dL) is useful criterion to determine the optimal timing of interval debulking surgery following neoadjuvant chemotherapy in epithelial ovarian cancer. Jpn J Clin Oncol, 46, 517-21. https://doi.org/10.1093/jjco/hyw029
  12. Samani AA, Yakar S, LeRoith D, Brodt P (2007). The role of the IGF system in cancer growth and metastasis: overview and recent insight. Endocr Rev, 28, 20-47. https://doi.org/10.1210/er.2006-0001
  13. Slipicevic A, Oy GF, Askildt IC, et al (2009). Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions. Hum Pathol, 40, 527-37. https://doi.org/10.1016/j.humpath.2008.10.003
  14. Spirina LV, Bochkareva NV, Kondakova IV, et al (2012). Regulation of insulin-like growth NF-kB proteasome system in endometrial cancer. Mol Biol (Mosk), 46, 452-60.
  15. Sodek KL, Murphy KJ, Brown TJ, Rinquette MJ (2012). Cellcell and cell-matrix dynamics in intraperitoneal cancer metastasis. Cancer Metastasis Rev, 31, 397-414. https://doi.org/10.1007/s10555-012-9351-2
  16. Stadlmann S, Amberger A, Pollheimer J, et al (2005). Ovarian carcinoma cells and IL-1beta-activated human peritoneal mesothelial cells are possible sources of vascular endothelial growth factor in inflammatory and malignant peritoneal effusions. Gynecol Oncol, 97, 784-9. https://doi.org/10.1016/j.ygyno.2005.02.017
  17. Thomsen J, Hjortebjerg R, Espelund U, et al (2015). PAPP-A proteolytic activity enhances IGF bioactivity in ascites from women with ovarian carcinoma. Oncotarget, 6, 32266-78. https://doi.org/10.18632/oncotarget.5010
  18. Verhaak RG, Tamayo P, Yang JY, et al (2013). Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest, 123, 517-25.
  19. Wang F, Ye Y, Xu X, et al (2013). CA-125-indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery. J Ovarian Res, 6, 14. https://doi.org/10.1186/1757-2215-6-14
  20. Weinberg LE, Rodriguez G, Hurteau JA, et al (2010). The role of neoadjuvant chemotherapy in treating advanced epithelial ovarian cancer. J Surg Oncol, 101, 334-43. https://doi.org/10.1002/jso.21482
  21. Yunusova NV, Spirina LV, Kondakova IV, et al. (2013). The relationship of metalloproteinase PAPP-A expression with the expression of growth and transcriptional factors in endometrial cancer. Biol Bull, 40, 253-9. https://doi.org/10.1134/S1062359013030114
  22. Yunusova NV, Kondakova IV, Kolomiets LA, et al (2015). The insulin-like growth factors system in ovarian cancer metastasis: the relation with p45 Ser ${\beta1$-catenin. Molekulyrnaya Meditsina, 4, 17-22. [in Russian].
  23. Yunusova NV, Spirina LV, Frolova AE, et al (2016). Association of IGFBP-6 expression with metabolic syndrome and with adiponectin and IGF-IR receptor levels in colorectal cancer. Asian Pac J Cancer Prev, 17, 3963-9.